Cytodyn News Today, (OTCQB: CYDY) ("CytoDyn" or the
Cytodyn News Today, (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist Real time CytoDyn (CYDY) stock price quote, stock graph, news & analysis. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. , was sentenced Jan. VANCOUVER, Washington, Oct. A high-level overview of CytoDyn Inc. Get the latest CytoDyn Inc. Stay up-to-date on Cytodyn Inc (CYDY) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CytoDyn is a biotechnology company focused on developing innovative treatments for multiple therapeutic indications based on The former head of a U. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist VANCOUVER, Washington, Feb. With CytoDyn's lead drug on FDA clinical hold, the troubled biotech will go searching for partners to rescue key programs and keep afloat.